Teva v. Allergan (cyclosporine)

Carlson Caspers represents Teva in an Inter Partes Review [IPR2017-00576; IPR2017-00578; IPR2017-00579; IPR2017-00583; IPR2017-00585; and IPR2017-00586] concerning Teva’s Paragraph IV ANDA challenge of 1 patent covering the active pharmaceutical ingredient (API) present in the drug cyclosporine (Restasis®), compositions containing the API, and methods of using the API. The IPR was filed during the related Hatch-Waxman patent litigation and is currently pending.